Population
HeLa cells infected with Coxsackievirus B3 (CVB3) at various multiplicities of infection (MOI 1 to 10)
Comparison
Inhibition of JNK1/2 or p38 MAPK vs CVB3-infected cells without inhibitors or…
Design
Preclinical
Follow-up
up to 24 hours post-infection
Authors
Loading...
p38 inhibition merits further preclinical study in viral myocarditis; leaves open clinical translation from Level 5 data.
The p38 MAPK pathway plays a critical role in Coxsackievirus B3 viral progeny release and virus-induced cell death, suggesting a potential therapeutic target for viral myocarditis.
Si et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: